Hepatitis B is an infectious inflammatory disease of the liver, which is caused by the hepatitis B virus (HBV). Nowadays, the dramatic development of new HBV inhibitors is focused on discovering diverse non-nucleoside compounds with either novel structures or new mechanisms of action. In this review, we focus on the recent advances in discovery, structural modifications and biological activities studies of several distinct classes of synthetic non-nucleoside small molecular compounds with new mechanisms.